Norditropin is a brand name for somatropin, a recombinant human growth hormone used to treat growth failure in children and growth hormone deficiency in adults [1][2]. The Norditropin Pen is a device designed for the injection of this medication [3].
What conditions does Norditropin treat?
Norditropin is indicated for the long-term treatment of growth failure in children who have not attained normal adult height due to a lack of growth hormone [1][2]. It is also used in adults to treat growth hormone deficiency [1][2].
How does the Norditropin Pen work?
The Norditropin Pen is a pre-filled injection device that contains Norditropin [3]. It simplifies the process of self-administering growth hormone injections, allowing for precise dosing [3]. The pen is designed for ease of use, with patients typically injecting the medication under the skin [3].
What are the potential side effects of Norditropin?
Potential side effects associated with Norditropin therapy can include injection site reactions, muscle pain, joint pain, fluid retention, and headaches [1]. In children, increased blood sugar levels and allergic reactions are also possibilities [1]. More serious but rare side effects can involve pancreatitis, carpal tunnel syndrome, and effects on thyroid function [1].
When does the patent for Norditropin expire?
Information regarding specific patent expiry dates for Norditropin is available through resources that track pharmaceutical patents. DrugPatentWatch.com provides detailed patent information, including expiry dates for various medications [4].
Are there alternative treatments for growth hormone deficiency?
Besides Norditropin, other brands of somatropin are available, such as Genotropin, Humatrope, and Omnitrope [1]. These are also recombinant human growth hormones [1]. The choice of medication and delivery device may depend on individual patient needs, physician recommendations, and insurance coverage.
What clinical data supports Norditropin's use?
Clinical trials have demonstrated the efficacy of Norditropin in promoting growth in children with growth hormone deficiency and in improving body composition and quality of life in adults with the condition [1]. These studies have informed its regulatory approval and ongoing use in patient care [1].
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020822s057,021396s013,021846s015lbl.pdf
[2] https://www.novonordisk.com/products/growth-disorders/norditropin.html
[3] https://www.norditropinhcp.com/hcp/norditropin-flexpro-pen
[4] https://www.drugpatentwatch.com/